Two Sigma Advisers LP Purchases 32,000 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Two Sigma Advisers LP lifted its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 74.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 74,800 shares of the company’s stock after acquiring an additional 32,000 shares during the quarter. Two Sigma Advisers LP owned approximately 0.05% of Vir Biotechnology worth $549,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in Vir Biotechnology by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 2,196,601 shares of the company’s stock worth $16,127,000 after buying an additional 7,827 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Vir Biotechnology by 58.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company’s stock valued at $14,059,000 after purchasing an additional 703,360 shares during the last quarter. Millennium Management LLC boosted its position in Vir Biotechnology by 55.3% during the fourth quarter. Millennium Management LLC now owns 1,715,083 shares of the company’s stock valued at $12,589,000 after purchasing an additional 610,367 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Vir Biotechnology by 10.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,252,655 shares of the company’s stock valued at $9,194,000 after purchasing an additional 118,379 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Vir Biotechnology by 4.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,237,600 shares of the company’s stock valued at $9,084,000 after purchasing an additional 55,300 shares during the last quarter. Institutional investors own 65.32% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Backer Marianne De sold 79,712 shares of Vir Biotechnology stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $5.95, for a total value of $474,286.40. Following the completion of the transaction, the chief executive officer now directly owns 769,505 shares of the company’s stock, valued at approximately $4,578,554.75. This trade represents a 9.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 16.00% of the company’s stock.

Vir Biotechnology Stock Up 3.3%

NASDAQ VIR opened at $5.24 on Wednesday. Vir Biotechnology, Inc. has a twelve month low of $4.32 and a twelve month high of $14.45. The company has a market cap of $723.68 million, a price-to-earnings ratio of -1.34 and a beta of 1.36. The business’s fifty day moving average is $5.44 and its 200 day moving average is $7.47.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.05). The firm had revenue of $3.03 million for the quarter, compared to analyst estimates of $8.59 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The company’s revenue was down 94.6% compared to the same quarter last year. During the same period last year, the business earned ($0.48) EPS. On average, research analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on VIR shares. Needham & Company LLC restated a “buy” rating and issued a $14.00 price objective on shares of Vir Biotechnology in a research note on Thursday, May 22nd. The Goldman Sachs Group lowered their price objective on Vir Biotechnology from $28.00 to $21.00 and set a “buy” rating on the stock in a research note on Thursday, April 17th. HC Wainwright restated a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, February 28th. Finally, Barclays raised their target price on Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $32.86.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).